Funmilayo Tade MD, MPH, Presenter: Nothing to Disclose

Oluwaseun Odewole MD, MPH, Abstract Co-Author: Nothing to Disclose

Oyeladun Oyenuga MD, MPH, Abstract Co-Author: Nothing to Disclose

Michael A. Cohen MD, Abstract Co-Author: Nothing to Disclose

Anna Irene Holbrook MD, Abstract Co-Author: Nothing to Disclose

Mary S. Newell MD, Abstract Co-Author: Nothing to Disclose

Bital Savir-Baruch MD, Abstract Co-Author: Nothing to Disclose

Toncred Styblo MD, MS, Abstract Co-Author: Nothing to Disclose

Mark M. Goodman PhD, Abstract Co-Author: Royalties, Nihon Medi-Physics Co, Ltd

David M. Schuster MD, Abstract Co-Author: Research funded, Nihon Medi-Physics Co, Ltd Expert Advisory Committee, AIM Specialty Health

Amino acid transport is upregulated in breast carcinoma. Anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-3-[18F]FACBC) is a synthetic amino acid analog positron emission tomography (PET) radiotracer which is transported primarily via system ASCT2 and LAT1 amino acid transporters. The purpose of this exploratory study is to characterize anti-3-[18F] FACBC uptake in benign and malignant breast lesions.

Four women with histologic confirmation of breast carcinoma or about to undergo biopsy for suspected breast carcinoma not currently undergoing therapy underwent 45 minute dynamic anti-3-[18F]FACBC PET-CT. Standardized uptake values (SUVs) within malignant and benign breast lesions as well as the contra-lateral normal breast were recorded at 5-8mins, 17-21mins, 29-32mins and 41-44mins time frames. Findings were validated by histologic and imaging correlation. T-tests were used to examine the significance of difference in the mean SUVmax of benign to malignant lesions as well as to normal breast tissue.

Average age ±SD was 64.25 ± 11.2 years. Average dose ±SD of anti-3-[18F] FACBC injected was 9.8mci ±0.3. There were 7 breast lesions characterized in 4 patients; 3 benign and 4 malignant (Figure 1A & B). Malignant lesions had significantly higher SUVmax compared to benign lesions and normal contra-lateral breast tissue at all time points (Figure 1C). There was no significant difference in the mean SUVmax of benign breast lesions and normal contra-lateral breast at any time point (Figure 1).

Anti-3-[18F] FACBC shows promise in delineating malignant from benign breast lesions and normal breast tissue. Our result may guide the design of larger studies examining its utility in breast cancer detection, staging and restaging.

Anti-3-[18F] FACBC characterization of amino acid transport upregulation may be useful for the diagnosis of breast cancer and to differentiate malignant from benign lesions.

Tade, F, Odewole, O, Oyenuga, O, Cohen, M, Holbrook, A, Newell, M, Savir-Baruch, B, Styblo, T, Goodman, M, Schuster, D, Amino Acid Transport Imaging of Breast Carcinoma via Anti-3-[18F] FACBC PET-CT: A Pilot Study.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14005681.html